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Abstract
Background: Lassa fever is a potentially fatal acute viral illness caused by Lassa virus which is carried by rodents
and is endemic in some West African countries. Importation of emerging infections such as Lassa fever, Ebola Virus
Disease and other viral hemorrhagic fevers into non endemic regions is a growing threat particularly as international
travel and commitments in resolving conflicts in endemic countries in the West Africa sub-region continue.
Case presentation: We report the first two recorded imported cases of Lassa fever among Ghanaian Peace keepers in
rural Liberia, who became ill while on Peace keeping mission. They were subsequently evacuated to the UN level IV
hospital in Accra, where their illnesses were laboratory confirmed. One of the patients recovered with ribavirin treatment
and supportive therapy. No secondary clinical cases occurred in Ghana.
Conclusions: Healthcare providers at all levels of care should thus have a high index of suspicion for these infectious
diseases and adopt standard infection control measures when treating patients in endemic regions or returning travelers
from an endemic region with a febrile illness even of a known etiology.
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Background
Lassa fever is an old age acute viral haemorrhagic illness
caused by Lassa virus, a rodent-borne arenavirus which
was discovered in 1969. The single-stranded RNA virus
is named after the town in Nigeria where the first cases
were isolated [1, 2]. The animal reservoir and vector for
Lassa fever is the “multimammate rat” (Mastomys nata-
lensis) [1, 3]. It is transmitted to humans from contact
with food or household items contaminated with rodent
excreta. Aerosol or airborne transmission may also occur
during cleaning activities, such as sweeping, when a per-
son inhales tiny air particles contaminated with infected
rodent excreta. Person-to-person infections and labora-
tory transmission is also possible, particularly in the ab-
sence of adequate infection control measures in the
healthcare environment [1, 2]. The virus can be isolated
in body fluids of infected persons including semen and
secretion of the virus can continue for 30 days and be-
yond from infected individuals [2].
Lassa fever occurs in both sexes and all age groups.
Classically signs and symptoms of the disease occur 6–
21 days after a person comes into contact with the virus
[1, 2]. Approximately 80 % of Lassa fever cases present
with mild symptoms such as mild fever, general malaise,
weakness, and headache, and are often undiagnosed. In
the remaining 20 % of infected individuals however, the
disease may progress to more serious symptoms includ-
ing high grade fever, sore throat, mucosal bleeding (from
gums, eyes, or nose, vagina as examples), respiratory dis-
tress, repeated vomiting, facial swelling, pain in the
chest, back, and abdomen, and shock. Neurological
problems have also been described, including hearing
deficit, seizures, meningitis and encephalitis. Approxi-
mately 15–20 % of patients hospitalized for Lassa fever
die from the illness. The case-fatality rate may reach
50 % in hospitalized patients during occasional Lassa
fever epidemics. Generally however, only 1 % of all Lassa
fever cases result in death [1, 2].
The disease is endemic in parts of West Africa par-
ticularly Sierra Leone, Liberia, Guinea and Nigeria [4]. It
is estimated that between 300,000 and 500,000 Lassa
fever cases and 5000 deaths occur annually in West
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Africa, indicating a high burden and impact on popula-
tions in these endemic regions [1, 2]. In some areas of
Sierra Leone and Liberia, 10–16 % of annual hospital ad-
missions are due to Lassa fever [1]. Neighboring coun-
tries however, remain at risk [4] as the rodent vector for
Lassa virus is ubiquitous throughout the region. Spor-
adic Lassa fever cases have been detected in Côte
d’Ivoire [5] and from travelers to Burkina Faso [6, 7].
There has been serologic evidence of Lassa virus infec-
tion in Ghana [8] as well as in Togo and Benin [9]. In
2009, the first case from Mali was reported in a traveler
living in southern Mali [10] whiles Ghana reported its
first cases amongst two locals living in the Ashanti re-
gion in October and December of 2011 [11]. Apart from
these two fatal sporadic cases in late 2011, there have
been no reports of imported cases from neighboring en-
demic countries especially Liberia, where Ghana has
been contributing Peacekeeping troops since the onset
of the crisis in the early 1990’s. Although travellers to
endemic countries are at risk of infection [7, 12–15], few
outbreaks have been reported among UN Peacekeepers
[16]. This paper reports the first two imported cases of
Lassa fever among Ghanaian UN Peacekeepers in rural
Liberia, who became ill while in country and were subse-
quently evacuated to the United Nations (UN) level IV
hospital in Accra, where their illnesses were laboratory
confirmed. With the detailed laboratory investigation
and molecular characterization of the virus described
[17], this case report discusses the clinical and epidemio-
logic investigations, the surveillance and management of




A 32 year old male Ghanaian soldier on UN peacekeep-
ing mission in Liberia who resided under remote rural
conditions at a new position in Zorzor, Lofa County, in
Northwestern Liberia for three and half months, re-
ported to the Company Aid Post (CAP) on 15th May,
2013 with complains of fever, chills, malaise and head-
aches. He was started on empirical treatment for malaria
and then referred to the UN Level 1 hospital for further
evaluation based on the suspicion of a possible viral
hemorrhagic fever considering the clinical course of a
previous case with who he shared the same living ac-
commodation. The index case had died 4 days earlier
with hemorrhagic signs following a febrile illness for
which he was being managed as a case of confirmed
malaria and a possible enteric fever. After 3 days at the
level 1 hospital being managed as a case of confirmed
malaria, his fever persisted and he also started passing
dark urine. He was then referred and admitted at the
UN level II hospital on the 22nd May, 2013 for further
evaluation and management. He was managed as a case
of acute renal failure due to black water fever (severe
Falciparum malaria). Patient’s condition however failed
to improve with a progressively deteriorating renal and
liver function as well as a low platelet count. He was
thus air-lifted using an air ambulance in a critical condi-
tion from Liberia to the 37 Military Hospital in Accra,
Ghana on the 26th of May 2013 at around 23:00 h. On
arrival the patient was alert and able to give a clear re-
port of his medical history complaining however of
vomiting and severe epigastric pain.
Physical examination showed a very ill looking young
man who was fully conscious but tachypnoeic (respiratory
rate: 36 cycles per minute), febrile with axillary temperature
of 38 °C, not pale but with a tinge of jaundice and mildly
dehydrated. His blood pressure was 120/90 mmHg and his
pulse rate was 68 beats per minute. The chest examination
was unremarkable. However, there was moderate general
abdominal tenderness with no rebound tenderness. Bowel
sounds were present and of normal frequency. An initial
diagnosis of viral haemorrhagic fever, probably Lassa fever
to rule out septicaemia was made.
Initial laboratory results showed haemoglobin of
12.8 g/dL, white cell count of 44.2 × 109/L and a platelet
count of 695 × 109/L. His ESR was 17 mm/h. Blood film
for malaria parasite was negative. His renal function was
impaired with urea of 27.5 mmol/L and creatinine of
637ummol/L. His electrolytes were however normal. His
liver function was also impaired with total bilirubin
of 50 μmol/L and AST and ALT of 1321 IU/L and
1060 IU/L respectively. Blood samples were sent to
the Noguchi Memorial Institute for Medical Research
(NMIMR) for laboratory testing of typical Viral Haemor-
rhage Fevers (VHFs) the same night.
Application of Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR) assay on blood sample confirmed the
presence of Lassa fever virus on 27th May, 2013. The pa-
tient was commenced on ribavirin regimen; 30 mg/kg IV
(maximum, 2 g) loading dose to be followed by 17 mg/
kg IV (maximum, 1 g/dose) 6 hourly for 4 days, then
8 mg/kg IV (maximum, 500 mg/dose) 8 hourly for
6 days in addition to other supportive treatment. Des-
pite intensive nursing and medical care, the patient’s
condition deteriorated rapidly on the second day of
admission and was later pronounced dead at 17:35 h
on the 27th May, 2013. No post-mortem examination
was undertaken. Blood culture results received later
did not show any bacterial growth.
Case 2
A 27 year-old male soldier on the same air ambulance as
Case 1 from Liberia also arrived at the 37 Military Hos-
pital on the 26th of May 2013 with a 5 days history of
fever, headache and 3 days history of diarrhea, vomiting,
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severe epigastric pain and passage of dark urine. His
urine output had also deceased over the period. He
shared living accommodation with case 1 and the index
case at their position in Zorzor, Lofa County, Liberia
and was also on admission at the UN Level II Hospital
in Liberia where he was also being managed as a case of
Black water fever due to severe falciparum malaria.
Physical examination showed an ill-looking young
man who was not pale or jaundiced but febrile with a
temperature of 39.2 °C. His pulse rate was 72 beats per
minute with a blood pressure of 110/70 mmHg. His re-
spiratory system was normal but had marked epigastric
tenderness. His central nervous system was grossly in-
tact. An initial diagnosis of complicated malaria with
gastritis to rule out Lassa fever was made. Blood sample
was also sent to NMIMR for confirmation of suspected
viral hemorrhagic fever using RT-PCR. Initial laboratory
investigations showed reduced hemoglobin of 9.3 g/dL,
low platelet count of 5.5 × 109/L, and white cell count of
5 × 109/L. Blood film for malaria parasites was negative.
His urea was 8.5 mmol/L and creatinine was 136 mmol/
L, his electrolytes were normal. His liver function test
and chest x-ray were normal. Results received on 27th
May, 2013 from NMIMR confirmed Lassa fever infec-
tion. Blood culture did not grow any organism. Patient
was commenced on IV ribavirin 2 g loading dose, then
1 g 6 hourly for 4 days followed by 500 mg 8 hourly for
6 days alongside other supportive treatment.
The patient’s urine output improved within the first
week of admission and his epigastric pain gradually re-
solved. He however continued to have loose stools and
occasional vomiting. During the second week of admis-
sion he was transfused with four pints of packaged cells
as his hemoglobin dropped to 6.8 g/dL with evidence of
hemolysis. The patient gradually regained his strength
and completed 10 days of ribavirin. Supportive treatment
with appropriate nutrition continued until he was dis-
charged without any obvious sequelae of Lassa fever in-
fection after 22 days of admission in the hospital with
instructions to avoid unprotected sexual intercourse for
2 months to reduce the risk of transmission of the virus
through sex.
Public health response and management of contacts
In view of previous reported outbreaks of Lassa fever in
Liberia [18], there was a high index of suspicion for the
imported cases. Consequently, In the UN level IV hos-
pital in Accra, the recommended barrier nursing tech-
niques were fully deployed to receive and admit the
patients into the holding rooms. The patients were iso-
lated and managed with strict infection control measures
including full body protection using personal protective
equipment. There were three levels of decontamination
before any medical personnel were allowed to attend to
the patient(s) with full protective measures including the
use of N95 respiratory masks, disposable protective body
gowns, shoe covers, eye goggles, headgear, and gloves.
All medical waste from the ward was incinerated daily.
Attending medical, nursing, pathology and allied health
professionals who were categorized as low risk were
made to monitor their own body temperature and report
this to the disease control officer by noon each day for
21 days following their last contact with a case or speci-
men. None of the personnel developed a fever or any
other symptoms suggestive of Lassa fever over the obser-
vation period.
Facts about the cases were communicated to relevant
local, national and international authorities including the
World health Organization (WHO), the United Nations
Mission in Liberia (UNMIL) Headquarters and the air
ambulance crew. The WHO was informed under the
International Health Regulations [19], through the
WHO Country Office, while the Ministry of Health was
notified through the disease surveillance unit of the
Ghana Health Service (GHS). The GHS responded ap-
propriately to media inquiries, confirming that there was
no risk to the general public resulting from the case.
Health talks on Lassa fever were organized for the
troops in Liberia and information sheets on Lassa fever
and the process of monitoring were made available to
the contacts and remaining contingent in Liberia.
All individuals with potential direct exposure to Lassa
virus through contact with any of the three cases or ex-
posure to bodily fluids required risk assessment. A five-
member Ghanaian medical team from the Battalion
headquarters in Liberia headed by a senior medical offi-
cer was assisted by the UNMIL medical unit and the
public health division of the Level IV hospital in Ghana,
to begin control measures in the Zorzor camp through
identification and categorization of personal contacts of
the cases, institution of daily temperature surveillance
for isolated close personal contacts and improving gen-
eral sanitation and hygiene in the camp. All contacts
were assigned to one of three categories depending on
their level of risk as no risk, low risk and high risk as re-
ported elsewhere [10] and managed accordingly. The 11
soldiers who shared living accommodation with the 3
cases were classified as potential high risk and evacuated
to a new room and quarantined for 21 days with twice
daily temperature surveillance and monitoring for signs
consistent with Lassa fever. The medical team donned
the appropriate personal protective equipment (PPE)
and observed standard infection prevention and control
measures. The remaining 66 soldiers who either had no
direct contact or only casual contact with the cases were
informed of the minimal risk and were provided with
adequate information about Lassa fever and advised to
monitor their own temperature and report any fever to
Kyei et al. BMC Infectious Diseases  (2015) 15:217 Page 3 of 5
the medical team for further evaluation. Movements into
and out of the camp were also restricted. Samples were
later taken from the 11 isolated close contacts and the 5
member onsite medical team by the UNMIL medical
unit’s investigative team for testing. Results from the
enzyme-linked immunosorbent assays (ELISA) per-
formed on the samples detected anti-Lassa fever IgM
and IgG antibodies in 4 out of the eleven close contacts.
These four new cases were further isolated and com-
menced on a course of IV ribavirin for 10 days. None of
the isolated close-contacts or those who subsequently
tested positive showed any overt signs of Lassa fever and
were thus discharged after completing the 21-day follow
up period. All international contacts including the UN
air ambulance crew and the Level II medical team were
followed up by the UNMIL medical unit’s incident con-
trol team and appropriately managed.
Discussion
This report describes the first cases of imported Lassa
fever diagnosed in Ghana as well as the first hospitalized
Lassa fever case in Ghana to survive the disease with
close follow up of contacts. The first two indigenous
cases diagnosed in the Amansie West district in Ghana
both resulted in fatalities [11]. The non-specific presen-
tation of Lassa fever often makes clinical diagnosis in
the absence of a high index of suspicion difficult. In the
cases described here, the reported confirmed diagnosis
of malaria obviously delayed the consideration of other
endemic diseases like Lassa fever as a potential cause for
the febrile illness. It is however, well established that
malaria and Lassa fever may coexist in the same individ-
ual [20]. A confirmation of malaria and a developing
renal impairment in the two imported cases may have
informed the diagnosis of black water fever. It is note-
worthy however that, while black water fever in adults
from hyper-endemic malaria regions is uncommon,
acute renal impairment in Lassa fever patients is not
[21]. With the backdrop of previous reports of Lassa
fever in Zorzor [18, 22], the characteristic manner in
which the index case’s illness progressed to bleeding and
the epidemiological link of the two subsequent cases to
the index case led to a high index of suspicion of Lassa
fever among the receiving Ghanaian medical team.
Additionally, the time to onset of the febrile illness in
the two imported cases with the characteristic incuba-
tion period for Lassa fever also alerted the Ghanaian
medical team to deploy the appropriate barrier precautions,
isolation and prompt diagnosis of Lassa fever in the
imported cases. Tissue samples of the first case who died in
Liberia were later sent to NMIMR after the two cases who
shared accommodation with him were confirmed to have
acquired Lassa fever. Immunohistochemistry and PCR
assay performed on the tissue samples later confirmed
Lassa fever and made him the missed index case.
Although the risk of human-to-human transmission of
Lassa fever is low, nosocomial transmission in the
healthcare environment has occurred in some endemic
areas [18, 22, 23] and an instance of asymptomatic sero-
conversion has been reported in a German physician
[12]. In these cases described, strict adherence to stand-
ard universal infection control practices to prevent un-
protected exposures to blood or other body fluids
resulted in successful case management with no second-
ary cases among medical personnel or visitors. With lim-
ited proven effectiveness and tolerability of oral ribavirin
prophylaxis [24], it was not recommended for persons
who might have been exposed to the cases described in
this report. Instead, a standard 10 days treatment regimen
of intravenous ribavirin was recommended for the 4 out of
the 11 soldiers who shared living accommodation with the
cases and showed asymptomatic seroconversion for Lassa
fever. After strict temperature surveillance and monitoring,
none of the contacts including the 7 other soldiers who had
some form of close contact with very ill cases developed an
illness consistent with Lassa fever.
Field investigation at the Zorzor camp confirmed ro-
dent activity as well as a hole in the floor of the room
where the infected cases lived. This finding indicated
how the soldiers in that room may have been exposed to
the Lassa virus which is shed in the urine and droppings
of the Mastomys rodents and transmitted through direct
contact with contaminated objects or food [1]. After fumi-
gation of the room and repair of the broken floor, other
measures were instituted to prevent rodents from entering
the inhabited areas. These included rodent traps, storage of
food and grain in rodent-proof containers, proper waste
disposal and the maintenance of general camp environmen-
tal hygiene. These measures as well as continued awareness
have been successful so far in preventing another outbreak
amongst the peacekeepers.
Conclusion
In a globalized world where nations and economies are
increasingly interdependent with vanishing trade restric-
tions and geographic boundaries, there is easy move-
ment and travel of humans and goods. The consequence
is the potential for rapid transfer of diseases from one
geographic region to the other and the likely events of
epidemics and outbreaks. Importation of emerging infec-
tions such as Lassa fever and other VHFs into non endemic
regions is a growing threat especially as international travel
and commitments in resolving conflicts in endemic coun-
tries in the West Africa sub-region persist. Healthcare pro-
viders should thus have a high index of suspicion for VHF
and adopt standard infection control measures when treat-
ing patients in endemic regions or returning travelers from
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an endemic region with a febrile illness even of a known
etiology. Surveillance of travel-associated diseases will be
important to provide the evidence for both pre- and post-
travel advice and interventions. In the event of an outbreak
with a dangerous pathogen such as the Lassa virus, adopt-
ing an appropriate public health response [24] and adhering
to strict infection control measures in providing care will
help curb the spread and prevent an epidemic.
Consent
Written informed consent was obtained from the surviv-
ing patient for publication of this case report. For the
deceased case, consent for publication was sought from
the next of kin (wife) of the patient. A copy of the writ-
ten consents are available for review by the Editor of this
journal.
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